Skip to main content

Wai Conrad's Form 4/A amendment

Amended

Clover Health Investments, Corp. (CLOV) · filed Jul 10, 2025

Accession no.
0001801170-25-000170
Filed
Jul 10, 2025
Trade date
Sep 13, 2024-Jul 8, 2025
Filing delay
300 days
Rule 10b5-1 plan
Checked
Original filed
Sep 17, 2024

This filing lists 2 non-derivative transactions. It carries over 2 transactions from the original filing that it did not restate. Open-market sales total $49.6K. It was filed 300 days after the trade.

This amendment restates part of 0001801170-24-000192 (filed Sep 17, 2024). The transactions it did not restate still count and are listed below.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Wai ConradCIK 0001971702Officer (CEO, Counterpart Health)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 13, 2024Class A Common StockAGrant or awardAcquired+379,866$0.00$01,699,767Direct
Jul 8, 2025Class A Common StockSSaleDisposed−15,203$3.26−$49,561.781,613,498Indirect

Carried over from the original filing

This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.

From 0001801170-24-000192 (filed Sep 17, 2024).

Non-derivative securities (Table I)

Non-derivative transactions carried over from 0001801170-24-000192
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 13, 2024Class A Common StockFTax withholdingDisposed−93,180$2.99−$278,608.22,950,349Direct
Sep 14, 2024Class A Common StockFTax withholdingDisposed−98,217$2.99−$293,668.832,852,132Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Represents restricted stock units ("RSUs"), each representing a right to a share of Class A Common Stock, earned in connection with the determination of the level of performance achievement in satisfaction of vesting conditions underlying a performance-based restricted share unit grant awarded on October 31, 2023. One-half of the number of earned restricted stock units vested and were settled on September 13, 2024, and the remaining one-half of the restricted stock units will vest on October 31, 2025, subject to the Reporting Person's continued employment on such vesting date. This Amendment is being filed to reflect the full number of RSUs that were achieved.

F2

Number reflects total directly held Class A Common Stock taking into account the amended number and subsequent transactions through July 10, 2025.

F3

The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 3, 2025. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.25 to $3.27, inclusive. The Reporting Person undertakes to provide to the SEC staff, the issuer, or any security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F4

Shares held in trust for the benefit of the Reporting Person's family, of which the Reporting Person is a co-trustee.

Read the full filing on SEC EDGAR (opens in a new tab)